Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, is launching three new doses of VANCO READYTM, expanding its range of room temperature stable, ready-to-use (RTU) Vancomycin injection premix bags.
The VANCO READYTM availability will now cover all relevant doses from 500 mg to 2 g in 250 mg increments.
The availability of 750 mg in 150 mL, 1.25 g in 250 mL and 1.75 g in 350 mL are joining our range of presentations launched in 2019 – 500 mg in 100 mL, 1 g in 200 mL, 1.5 g in 300 mL and 2 g in 400 mL.
VANCO READYTM should not be administered during pregnancy, please see boxed warning below.
Carl-Åke Carlsson, Xellia’s CEO said: “With all seven VANCO READYTM presentations, Xellia can service the majority of needs of healthcare professionals in the vancomycin injection market. The success of our first four products has resulted in over 2,000 US institutions using VANCO READYTM. Since our announcement of approval, we have already seen strong interest and demand for the new codes from healthcare professionals on the basis of the product being room temperature and the most ready to use product available.”
Vancomycin Injection is a glycopeptide antibacterial indicated in adult and pediatric patients (1 month and older) for the treatment of septicemia (sepsis), infective endocarditis, skin and skin structure infections, bone infections and lower respiratory tract infections.
Craig Boyd, Xellia’s North American President said: “One of the uses for Vancomycin in the US is in the treatment of sepsis. The timely initiation of effective antibiotic treatments is universally recognized as a key intervention in the management of this life-threatening state as well as other infections. We are pleased to have been able to expand the range of doses available to clinicians, broadening their options to aid rapid and effective treatment.”
In the United States, sepsis is the third leading cause of death after heart disease and cancer, affecting more than 1.7 million people and killing more than 270,000 people within a single year1.
“Our room-temperature-stable VANCO READYTM premix has been critical in providing a truly ready Vancomycin Injection product. It aligns with recommendations from US agencies – such as the American Society of Hospital Pharmacists (ASHP), Institute for Safe Medication Practices (ISMP) and Joint Commission – to use manufacturer-prepared products as part of safe medication practice. We will continue to build on this success and focus on our ready-to-use product pipeline and partnerships during 2020.”
– Ends –
1 Rhee, C. et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA 318, 1241–1249 (2017).
Full prescribing information for Vancomycin Injection Premix RTU can be found at www.vancoready.com and www.xellia.com/us
About Vancomycin Injection
Vancomycin Injection, Ready to use (RTU) is a proprietary formulation of vancomycin, provided as a premixed solution in single-dose flexible bags, stable at room temperature (up to 25 °C) for 16